# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2021 Earnings Results

**Report date:** 2022-02-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2021

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.37%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $23.72 | N/A | +28.26% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the earnings results, highlighting their commitment to innovation. They emphasized the importance of continuing to meet patient needs in the coming quarters.

**Key quotes:**

> We are pleased with our performance this quarter.

> Our focus remains on innovation and meeting patient needs.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported strong earnings with an EPS beat, which contributed to a slight increase in stock price. The positive surprise in EPS indicates strong operational performance, although no revenue figures were disclosed. The stock reaction suggests that investors are encouraged by the earnings results, even without specific guidance for the future.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2021_